Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone Skin
Retrieved on:
금요일, 1월 10, 2020
Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future License Agreement.
Key Points:
- Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future License Agreement.
- Prospective areas of application include medicated skin care products for sensitive, eczema-prone skin as well as therapeutic products for skin diseases such as atopic dermatitis.
- The skin microbiome offers a promising platform for the development and commercialization of natural skin care products more and more people are looking for.
- Azitra, Inc. is a clinical-stage medical dermatology company that combines the power of the microbiome with cutting-edge genetic engineering to treat skin disease.